基石藥業-B(02616.HK)首次披露兩款自身免疫/炎症性疾病全新雙抗分子靶點
格隆匯7月3日丨基石藥業-B(02616.HK)發佈公告，公司首次披露兩款自主研發、針對自身免疫/炎症性疾病的雙特異性抗體藥物靶點：CS2013(B細胞激活因子[BAFF]/ 增殖誘導配體[APRIL])；和CS2015(OX40配體[OX40L]/ 胸腺基質淋巴細胞生成素[TSLP])。這兩款藥物具備同類最佳/同類首創潛力，目前均處於臨牀前候選化合物(PCC)確認階段，臨牀前研究數據將在相關國際學術會議上公佈。此外，基石藥業計劃於2025年下半年啓動新藥臨牀試驗申請(IND)準備工作。
根據披露，CS2013通過差異化分子設計同步阻斷B細胞和漿細胞發育及存活所需的兩個關鍵配體-BAFF與APRIL，臨牀前研究顯示其可觸發高效協同效應；同時較融合蛋白類藥物具備更優的藥代動力學特性，例如較長的半衰期，潛在更長的給藥間隔，支持皮下給藥等。擬開發適應症包括系統性紅斑狼瘡(SLE)、類風溼性關節炎(RA)、IgA腎病(IgAN)等多種B細胞相關自身免疫性疾病。
CS2015作爲一款潛在同類首創、同時靶向OX40L(免疫應答細胞上的關鍵配體)和TSLP(上皮細胞分泌的重要預警分子)的雙抗，通過雙重抑制Th2介導炎症反應的關鍵調控因子，爲特應性皮炎(AD)、哮喘等2型炎症性疾病提供新的治療策略；臨牀前數據同樣顯示其具備長半衰期與皮下給藥潛力。
基石藥業首席執行官、研發總裁、執行董事楊建新博士表示：“自身免疫/炎症性疾病領域在全球範圍內存在顯着未滿足需求-疾病種類繁多、患者基數龐大、且多數需要終身用藥，使其逐漸成爲僅次於腫瘤的第二大疾病市場。與現有單抗藥物相比，基石藥業的CS2013有望通過對成熟靶點的協同阻斷實現治療升級， CS2015則有望開創全新作用機制，兩款藥物共同體現了我們拓展非腫瘤管綫的戰略佈局，也是基石藥業踐行‘創新爲驅動，成爲改善全球患者健康的引領着’願景的重要實踐。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
